Заключение

В связи с важностью поиска надежных биомаркеров ранних стадий развития БА и дифференциальной диагностики синдрома МКС, а также создания удобных и недорогих тестов для их широкого практического применения необходимо учитывать, что любые предлагаемые молекулярные характеристики должны пройти глубокое и всестороннее тестирование с использованием как можно больших когорт пациентов с четко установленным диагнозом, а также фено- и генотипированием.

Литература

Бурбаева Г.Ш., БокшаИ.С., Савушкина О.К., и др. Активность тромбоцитарной цитохром с-оксидазы и количество фермента метаболизма глутамата при синдроме мягкого когнитивного снижения // Журнал неврол. и псих. им. С.С. Корсакова. 2012. Т 112. № 2. С. 55-58.

Гаврилова С.И., Левин О.С., Жданеева Л.В. Неврологические нарушения при болезни Альцгеймера // Журнал неврол. и псих. им. С.С. Корсакова. 2010. Т 110. № 7. С. 4-8.

Гаврилова С.И., Федорова Я.Б., Гантман М.В. и др. Опыт клинического применения препарата Цераксон (цитиколин) в лечении синдрома мягкого когнитивного снижения // Психиатрия. 2011а. № 1. С. 45-51.

Гаврилова С.И., Федорова Я.Б., Калын Я.Б. и др. Цераксон (цитиколин) в лечении синдрома мягкого когнитивного снижения (Mild cognitive impairment) // Журнал неврол. и псих. им. С.С. Корсакова. 2011б. Т 111. № 12. С. 16-20.

Журавин И.А., Багрова Д.И., Гаврилова С.И и др. Исследование механизмов регуляции амилоид- деградирующих ферментов и их роли в патогенезе когнитивных расстройств // Нейрохимические подходы к исследованию функционирования мозга.

Наливаева Н.Н., Беляев Н.Д., Tернер А.Дж. и др. Роль ферментов метаболизма амилоидного пептида в патогенезе деменции альцгеймеровского типа: поиск методов ранней диагностики и лечения // Психиатрия. 2008. № 4-6. С. 34-42.

Наливаева Н.Н., Макова Н.З., Кочкина Е.Г. и др. Влияние геропротекторных пептидов на активность холинэстераз и образование растворимой формы предшественника амилоидного пептида в клетках нейробластомы человека SH-SY5Y // Нейрохимия. 2011. Т 28. С. 200-207.

Яхно Н.Н. Когнитивные расстройства в неврологической практике // Невролог журнал. 2006. № 1. С. 4-12.

Appleyard M.E, McDonald B. Acetylcholinesterase and butyrylcholinesterase activities in cerebrospinal fluid from different levels of the neuraxis of patients with dementia of the Alzheimer type // J. Neurol. Neurosurg. Psychiatry. 1992. Vol. 55. P. 1074-1078.

Arendt T., Bruckner M.K., Lange M., Bigl V. Changes in acetylcholinesterase and butyrylcholinesterase in Alzheimer’s disease resemble embryonic development - a study of molecular forms // Neurochem. Int. 1992. Vol. 21. P. 381-396.

Bjorkqvist M, Ohlsson M., Minthon L., Hansson O. Evaluation of a previously suggested plasma biomarker panel to identify Alzheimer’s disease // PLoS One. 2012. Vol. 7. P. e29868.

Boksha I.S., Tereshkina E.B., Burbaeva G.S. Glutamine synthetase and glutamine synthetase-like protein from human brain: purification and comparative characterization // J. Neurochem. 2000. Vol. 75. P. 2574-2582.

BradshawE.M, ChibnikL.B., KeenanB.T. etal. CD33 Alzheimer’s disease locus: altered monocyte function and amyloid biology // Nat. Neurosci. 2013. Vol. 16. P. 848-850.

Brown R.K., Bohnen N.I., Wong K.K. et al. Brain PET in suspected dementia: patterns of altered FDG metabolism // Radiographics. 2014. Vol. 34. P. 684-701.

Burbaeva G.Sh., Boksha I.S., Tereshkina E.B., et al. Glutamate metabolizing enzymes in prefrontal cortex of Alzheimer’s disease patients // Neurochem. Res.

Cardoso S.M., Proenga M.T., Santos S., Santana I., Oliveira C.R. Cytochrome c oxidase is decreased in Alzheimer’s disease platelets // Neurobiol. Aging. 2004. Vol. 25. P. 105-110.

Cheng L., Quek C.Y., Sun X. et al. The detection of microRNA associated with Alzheimer’s disease in biological fluids using next-generation sequencing technologies // Front. Genet. 2013. Vol. 4. P 150.

Chincarini A., Bosco P., Calvini P. et al. Local MRI analysis approach in the diagnosis of early and prodromal Alzheimer’s disease // Neuroimage. 2011. Vol. 58. P. 469-480.

Dennis E.L., Thompson PM. Functional brain connectivity using fMRI in aging and Alzheimer’s disease // Neuropsychol. Rev. 2014. Vol. 24. P. 49-62.

DrzezgaA. Amyloid-plaque imaging in early and differential diagnosis of dementia // Ann. Nucl. Med. 2010. Vol. 24. Р 55-66.

Drzezga A., Barthel H., Minoshima S., Sabri O. Potential clinical applications of PET/MR imaging in neurodegenerative diseases // J. Nucl. Med. 2014. Vol. 55. Suppl. 2. Р. 47S-55S.

Dudley E., Hassler F., Thome J. Profiling for novel proteomics biomarkers in neurodevelopmental disorders // Expert Rev. Proteomics. 2011. Vol. 8. P. 127-136.

Escott-Price V, Bellenguez C., Wang L. et al. Gene-wide analysis detects two new susceptibility genes for Alzheimer’s disease // PLoS One. 2014. Vol. 9. P. e94661.

Ferreira D., Perestelo-Perez L., Westman E. et al. Meta-review of CSF core biomarkers in Alzheimer’s disease: The state-of-the-art after the new revised diagnostic criteria // Front. Aging Neurosci. 2014. Vol. 6. P. 47.

FiskL., Nalivaeva N.N., Boyle J.P. et al. Effects of hypoxia and oxidative stress on expression of neprilysin in human neuroblastoma cells and rat cortical neurones and astrocytes // Neurochem. Res. 2007. Vol. 32. P 1741-1748.

Frangois M, Leifert W., Hecker J. et al. Altered cytological parameters in buccal cells from individuals with mild cognitive impairment and Alzheimer’s disease // Cytometry A.

Frangois M., Leifert W., Martins R. et al. Biomarkers of Alzheimer’s disease risk in peripheral tissues; focus on buccal cells // Curr. Alzheimer Res. 2014b. Jun 17. [Epub ahead of print].

Frankfort S.V, Tulner L.R., van Campen J.P. et al. Amyloid P protein and tau in cerebrospinal fluid and plasma as biomarkers for dementia: a review of recent literature // Curr. Clin. Pharmacol. 2008. Vol. 3. P 123-131.

Haroutunian V., Hoffman L.B., Beeri M.S. Is there a neuropathology difference between mild cognitive impairment and dementia? // Dialogues Clin. Neurosci. 2009. Vol. 11. P. 171-179.

HuangJ.Y.,HafezD.M., JamesB.D. etal. Altered NEP2 expression and activity in mild cognitive impairment and Alzheimer’s disease // J. Alzheimers Dis. 2012. Vol. 28. P. 433-441.

Jack C.R. Jr., Wiste H.J., Vemuri P. et al. Brain P-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer’s disease // Brain. 2010. Vol. 133. Р. 3336-3348.

Kiddle S.J., Sattlecker M., Proitsi P. et al. Candidate blood proteome markers of Alzheimer’s disease onset and progression: a systematic review and replication study // J. Alzheimers Dis. 2014. Vol. 38. P. 515531.

Lambert J.C., Ibrahim-Verbaas C.A., Harold D. et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease // Nat. Genet. 2013. Vol. 45. P. 1452-1458.

Lista S., Faltraco F., Prvulovic D., Hampel H. Blood and plasma-based proteomic biomarker research in Alzheimer’s disease // Prog. Neurobiol. 2013. Vol. 101-102. P. 1-17.

Liu Y, Studzinski C., Beckett T. et al. Circulating neprilysin clears brain amyloid // Mol. Cell Neurosci. 2010. Vol. 45. P 101-107.

Lukiw W.J., Andreeva T. V., Grigorenko A.P., Rogaev E.I. Studying micro RNA function and dysfunction in Alzheimer’s disease // Front. Genet. 2013. Vol. 3. P. 327.

Maccioni R.B., Lavados M., Maccioni C.B., Mendoza-Naranjo A.

Maddalena A., Papassotiropoulos A., Muller-Tillmanns B. et al. Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to beta-amyloid peptide42 // Arch. Neurol. 2003. Vol. 60. P. 1202-1206.

Manczak M., Park B.S., Jung Y., Reddy P.H. Differential expression of oxidative phosphorylation genes in patients with Alzheimer’s disease: implications for early mitochondrial dysfunction and oxidative damage // Neuromolecular. Med. 2004. Vol. 5. P. 147-162.

Marksteiner J., Pirchl M. Ullrich C. et al. Analysis of cerebrospinal fluid of Alzheimer patients. Biomarkers and toxic properties // Pharmacology. 2008. Vol. 82. P. 214-220.

McKhann G.M., Knopman D.S., Chertkow H. et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease // Alzheimers Dement. 2011. Vol. 7. P. 263-269.

Miyashita A., Koike A., Jun G. et al. SORL1 is genetically associated with late-onset Alzheimer’s disease in Japanese, Koreans and Caucasians // PLoS One. 2013. Vol. 8. P. e58618.

Nalivaeva N.N., Beckett C., Belyaev N.D., Turner A.J. Are amyloid-degrading enzymes viable therapeutic targets in Alzheimer’s disease? // J. Neurochem. 2012a. Vol. 120. Suppl. 1. P. 167-185.

Nalivaeva N.N., Belyaev N.D., Zhuravin I.A., Turner A.J. The Alzheimer’s amyloid-degrading peptidase, neprilysin: can we control it? // Int. J. Alzheimers Dis. 2012b. Vol. 2012. Art. JD. P. 383796.

Noel-Storr A.H., Flicker L., Ritchie C.W. et al. Systematic review of the body of evidence for the use of biomarkers in the diagnosis of dementia // Alzheimers Dement. 2013. Vol. 9. P. e96-e105.

O'Bryant S.E., Xiao G., Barber R. et al. A serum protein-based algorithm for the detection of Alzheimer disease // Arch.

Petersen R.C. Mild cognitive impairment. Ageing to Alzheimer’s disease. Oxford University Press Inc., 2003.

Petersen R.C., Stevens J.C., GanguliM. et al. Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology // Neurology. 2001. Vol. 56. P 1133-1142.

Posner H.B., Cano S., Carrillo M.C. et al. Establishing the psychometric underpinning of cognition measures for clinical trials of Alzheimer’s disease and its precursors: a new approach // Alzheimers Dement. 2013. Vol. 9. Suppl. 1. P S56-60.

Prokselj T., Jerin A., Muck-Seler D., Kogoj A. Decreased platelet serotonin concentration in Alzheimer’s disease with involuntary emotional expression disorder // Neurosci. Lett. 2014. Vol. 578C. P 71-74.

Rissman R.A., Trojanowski J.Q., Shaw L.M., Aisen P.S. Longitudinal plasma amyloid P as a biomarker of Alzheimer’s disease // J. Neural. Transm. 2012. Vol. 119. P 843-850.

Ritchie C., Smailagic N., Noel-Storr A. et al. Plasma and cerebrospinal fluid amyloid P for the diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI) // Cochrane Database Syst. Rev. 2014. Vol. 6. P CD008782.

Sagare A.P., BellR.D., Zlokovic B.V Neurovascular dysfunction and faulty amyloid P-peptide clearance in Alzheimer disease // Cold Spring Harb. Perspect. Med. 2012. Vol. 2. P. a011452.

Sattlecker M., Kiddle S.J., Newhouse S. et al. Alzheimer’s disease biomarker discovery using SOMAscan multiplexed protein technology // Alzheimers Dement. 2014. Apr 24. pii: S1552-5260(14)00031-4. doi: 10.1016/j.jalz.2013.09.016. [Epub ahead of print].

Schifilliti D., Santamaria L.B., Rosa G. et al. Cholinergic central system, Alzheimer’s disease, and anesthetics liaison: a vicious circle? // J. Alzheimers Dis. 2010. Vol. 22. Suppl. 3. P. 35-41.

Shad K.F., Aghazadeh Y., Ahmad S., Kress B. Peripheral markers of Alzheimer’s disease: surveillance of white blood cells // Synapse. 2013. Vol. 67. P. 541-543.

Sheinerman K.S., Tsivinsky V.G., Abdullah L. et al. Plasma microRNA biomarkers for detection of mild cognitive impairment: biomarker validation study // Aging (Albany NY). 2013. Vol. 5. P. 925-938.

Shi H., Belbin O., Medway C. et al. Genetic variants influencing human aging from late-onset Alzheimer’s disease (LOAD) genome-wide association studies (GWAS) // Neurobiol. Aging. 2012. Vol. 33. P. 1849. e5-18.

Slaets S., Le Bastard N., Theuns J. et al. Amyloid pathology influences ap1-42 cerebrospinal fluid levels in dementia with Lewy bodies // J. Alzheimers Dis. 2013. Vol. 35. P. 137-146.

Spigset O., Wilhelmsson C., Mjorndal T., Eriksson S. Serotonin 5-HT2A receptor binding in platelets from patients with Alzheimer’s disease or vascular dementia // Int. Psychogeriatr. 2000. Vol. 12. P. 537-545.

Talib L.L., Joaquim H.P., Forlenza O.V. Platelet biomarkers in Alzheimer’s disease // World J. Psychiatry. 2012. Vol. 2. P. 95-101.

Tang K., Hynan L.S., Baskin F., RosenbergR.N. Platelet amyloid precursor protein processing: a bio-marker for Alzheimer’s disease // J. Neurol. Sci. 2006. Vol. 240. P. 53-58.

Tikkanen I., Salmela K., Hohenthal U. et al. Increased serum neutral endopeptidase activity in acute renal allograft rejection // Am. J. Nephrol. 1996. Vol. 16. P. 273-279.

Veitinger M, Varga B., Guterres S.B., Zellner M. Platelets, a reliable source for peripheral Alzheimer’s disease biomarkers? // Acta Neuropathol. Commun. 2014. Vol. 2. P. 65.

Velayudhan L., Ryu S.H., Raczek M. et al. Review of brief cognitive tests for patients with suspected ъmanagement of Alzheimer’s disease and other disorders associated with dementia: EFNS guideline // Eur J. Neurol. 2007. Vol. 14. P. e1-26.

Wang S., Wang R., Chen L. et al. Expression and functional profiling of neprilysin, insulin-degrading enzyme, and endothelin-converting enzyme in prospectively studied elderly and Alzheimer’s brain // J. Neurochem. 2010. Vol. 115. P. 47-57.

Yang M., Yi X., Wang J., Zhou F. Electroanalytical and surface plasmon resonance sensors for detection of breast cancer and Alzheimer’s disease biomarkers in cells and body fluids // Analyst. 2014. Vol. 139. P. 1814-1825.

Youn Y.C., Park K.W., Han S.H., Kim S. Urine neural thread protein measurements in Alzheimer disease // J. Am. Med. Dir. Assoc. 2011. Vol. 12. P. 372-376.